CN102836228A - Chinese medicinal composition for treating conjunctivitis and preparation method and application thereof - Google Patents
Chinese medicinal composition for treating conjunctivitis and preparation method and application thereof Download PDFInfo
- Publication number
- CN102836228A CN102836228A CN2012103802575A CN201210380257A CN102836228A CN 102836228 A CN102836228 A CN 102836228A CN 2012103802575 A CN2012103802575 A CN 2012103802575A CN 201210380257 A CN201210380257 A CN 201210380257A CN 102836228 A CN102836228 A CN 102836228A
- Authority
- CN
- China
- Prior art keywords
- parts
- conjunctivitis
- chinese medicine
- medicine composition
- radix
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a Chinese medicinal composition for treating conjunctivitis, belonging to the technical field of Chinese medicines. The Chinese medicinal composition is prepared from 15 parts of baikal skullcap root, 6 parts of honeysuckle flower, 10 parts of divaricate saposhnikovia root, 10 parts of virgate wormwood herb, 10 parts of szechuan lovage rhizome, 20 parts of dandelion, 20 parts of cicada shell, 10 parts of gentian, 5 parts of white paeony root, 5 parts of mint and 10 parts of liquoric root. The Chinese medicinal composition has good treatment effects on the aspect of treatment of inflammatory conjunctivitis, bacterial conjunctivitis, viral conjunctivitis and allergic conjunctivitis, and has a remarkable clinical popularization value.
Description
Technical field
The invention belongs to the Chinese medicine technical field, be specifically related to a kind of Chinese medicine composition of treating conjunctivitis.
Background technology
Conjunctivitis (conjunctivitis) is the commonly encountered diseases of ophthalmology, the general designation of the inflammatory reaction that to be conjunctival tissue take place in the effect of extraneous and body oneself factor.Because most of conjunctiva directly contacts with extraneous; Therefore receive easily infectious in the surrounding (as antibacterial, virus, and chlamydia etc.) and the stimulation of non-infectious factor (wound, chemical substance and physical factor etc.); And the blood vessel of conjunctiva and lymphoid tissue are abundant, and self and extraneous antigen make its sensitization easily.
Though the sickness rate of conjunctivitis confirms at present as yet, whenever Xia Qiu comes interim because the damp and hot bacterial reproduction that is beneficial to of weather, primary disease is outbreak of epidemic in the certain limit very easily.Some coastal cities particularly are because the damp and hot bacterial reproduction much human that is beneficial to of weather can be suffered from acute conjunctivitis.Because during this onste, photophobia arranged, shed tears, twinge and thin secretions is arranged, eyelid swelled simultaneously, the eye conjunctiva is because of the blood vessel of expansion and hemorrhagely make it to become redness.Hurried the breaking with tremendous force of its onset having a strong impact on the people's work life, also can change into chronic conjunctivitis like untimely treatment.Though conjunctivitis itself is general and not serious to eyesight influence, when its inflammation involves cornea or leads to complications, can cause the infringement of vision.
Generally adopt antimicrobial ointment or eye drip medicine to treat for infectious acute conjunctivitis clinically at present; Symptom can be eliminated in 1 thoughtful 6 weeks after medication usually; But the relapse rate of conjunctivitis is higher in the therapeutic process; And eye drop can cause a large amount of volatilizations of tear to be prone to cause xerophthalmia when using, having a strong impact on patient's work and life.Clinically for season anaphylaxis conjunctivitis treatment adopt the eye drop eye drip to merge usually to take Claritin and treat; And obtained good clinical short-term curative effects; But because these Western medicine mostly have potential hepatotoxicity; And action target spot is single, takes the health status that can influence the patient for a long time.Therefore researching and developing the effective medicine of a kind of conjunctivitis is of great practical significance.
Chinese medicine conjunctivitis historical of long standing and well established, and as an importance of modern oculopathy Comprehensive Treatment, more and more receive publicity in recent years.Zhang Yanli uses in " Chinese medicine moves back the observation of curative effect of red collyrium to acute conjunctivitis " and moves back red collyrium flushing conjunctival sac treatment acute conjunctivitis and obtained the good clinical therapeutic effect.Wu Qingbo discloses a kind of Chinese medicine compound (Herba Schizonepetae 10g, art thief 10g, Flos Chrysanthemi Indici 12g, Periostracum Cicadae 10 g in " effect of herbal fumigation in the treatment vernal conjunctivitis observed "; Fructus Kochiae 10g, Fructus Atriplicis Sibiricae 10g, Radix Aconiti Preparata 3 g, Herba Asari 3g Herba Siegesbeckiae 15g, Radix Sophorae Flavescentis 10g, Zaocys l0 g, Radix Platycodonis 10g; Semen Armeniacae Amarum 10g, Cortex Dictamni 12g, Radix Glycyrrhizae 12g), the smoked earlier back of this medicine clothes can have the effect of treatment and prevention of recurrence to vernal conjunctivitis.
Make a general survey of the research direction of world's new drug, mainly be single chemicals of research and development and preparation thereof the eighties in the past, begins to develop biotechnology and natural medicinal plants after the eighties, and the drug research direction is tending towards multiformity.In conjunction with the modern Chinese medicine theory of development, from improving the angle of curative effect of medication, reduction side effect, through Chinese medicine ingredients being screened the preparation that extraction and/or compatibility make, its side effect is little, and is safe, has the advantage that chemical synthetic drug can not be compared.
Summary of the invention
Deficiency to present conjunctivitis clinical treatment medicine; First purpose of the present invention is to provide a kind of Chinese medicine composition of treating conjunctivitis, and this Chinese medicine composition has good therapeutic effect aspect the struvite conjunctivitis of treatment, bacterial conjunctivitis, viral conjunctivitis and the anaphylaxis conjunctivitis.
The present invention treats the Chinese medicine composition of conjunctivitis; Raw material by following weight portion makes: 15 parts of Radix Scutellariaes, 6 parts of Flos Loniceraes, windproof 10 parts, 10 parts of Herba Artemisiae Scopariaes, 10 parts of Rhizoma Chuanxiongs, 20 parts of Herba Taraxacis, 20 parts of Periostracum Cicadaes, 10 parts of Radix Gentianaes, 5 parts of the Radix Paeoniae Albas, 5 parts of Herba Menthaes, 10 parts in Radix Glycyrrhizae.
Radix Scutellariae another name Radix Scutellariae, tsuchikane tea root are labiate, are used as medicine with root.Heat clearing and damp drying is arranged, and removing heat from blood is antiabortive, detoxicating functions.Cure mainly diseases such as epidemic febrile disease, upper respiratory tract infection, cough due to lung-heat, damp and hot jaundice, pneumonia, dysentery, hemoptysis, conjunctival congestion, frequent fetal movement, hypertension, carbuncle furuncle.
Flos Lonicerae is Caprifoliaceae woodbine Radix Ophiopogonis and congener dry flower or the first flower of opening of band.Flos Lonicerae is described as the good medicine of heat-clearing and toxic substances removing from ancient times.The sweet cold of its property fragrance, clearing away heat with drugs sweet in flavor and cold in nature and not injuring one's stomach, fragrance reaches thoroughly and can be eliminating evil.Flos Lonicerae can dispelling wind-heat, and also kind removing summer-heat blood poison is used for various febrile diseases, and like fever of the body, dermexanthesis, send out cards such as speckle, pyretic toxicity carbuncle sore, laryngopharynx swelling and pain, all effect is remarkable.Modern medicine shows; Flos Lonicerae contains cyclohexanhexanol, flavonoid, inositol, Saponin and tannin etc.; Has broad-spectrum antibacterial action; Various pathogens such as staphylococcus aureus, dysentery bacterium all there is stronger inhibitory action, several diseases pathogenic microorganisms such as leptospira, influenza virus and pathogenic moulds are also had inhibitory action.In addition, Flos Lonicerae also has tangible antiinflammatory and refrigeration function, and Flos Lonicerae water and steeping in wine liquid have tangible lethal effect to tentative tumor cell.
Windproof is the windproof root of Umbelliferae herbaceos perennial, main product in Heilungkiang, ground such as Sichuan, the Inner Mongol.Its acrid in the mouth, sweet, slightly warm in nature.Return bladder, liver, spleen channel; Has the effect that expelling pathogenic wind from the body surface, removing dampness to relieve pain, relieving convulsion are jerked surely.Cure mainly expelling pathogenic wind from the body surface; Removing dampness to relieve pain; Spasmolytic; Antipruritic.Main affection of exogenous wind-cold; The headache general pain; Rheumatic arthralgia; Joint is ached; Stomachache is had loose bowels; Discharging fresh blood stool; Tetanus; The rubella pruritus; Skin infection from the beginning of.Be used for headache due to common cold, rheumatic arthralgia, rubella pruritus, diseases such as tetanus
Herba Artemisiae Scopariae has the effect of clearing away heat-damp and promoting diuresis, jaundice eliminating, cures mainly diseases such as jaundice, dysuria, eczema pruritus, infectious jaundice type hepatitis.Modern pharmacology research Herba Artemisiae Scopariae has function of gallbladder promoting, effects such as liver function protecting, analgesic, antiinflammatory, blood fat reducing, blood pressure lowering, coronary dilating.
The hot temperature of Rhizoma Chuanxiong is fragrant dry, walks and does not keep, can go diffusing, the up top, mountain peak that reaches; Go into blood system again, the descending sea of blood that reaches.The blood circulation promoting and blood stasis dispelling action range, the suitable various diseases of stagnation of blood stasis; Wind-expelling pain-stopping, effectiveness is excellent, can control diseases such as wind syndrome of head headache, rheumatic arthralgia.
Dandelion Compositae herbaceos perennial.Contain multiple health-nutrition compositions such as taraxol, taraxacin, choline, organic acid, inulin in the Herba Taraxaci plant, effects such as diuresis, cathartic, jaundice eliminating subcutaneous ulcer, function of gallbladder promoting are arranged.According to the Compendium of Material Medica record, its property is put down sweet and slightly bitter taste, and heat-clearing and toxic substances removing, dispersing swelling and dissipating binds and galgctogogue action are arranged, to the treatment mastitis very effectively.It is oral no matter to fry in shallow oil juice, or the smash to mud external application, and effect is all arranged.In addition, Herba Taraxaci also has effects such as diuresis, cathartic, jaundice eliminating subcutaneous ulcer, function of gallbladder promoting, is widely used in clinical.
Periostracum Cicadae has the dispelling wind and heat pathogens effect, is used for wind heat table disease and often cooperates Herba Menthae to be equal to usefulness; The function that the rubella pruritus is also had dispelling wind for relieving itching.Clinically cure mainly diffusing wind heat, lung qi dispersing is decided convulsion.Control affection due to external wind and heat, the cough hoarseness, measles is sent out not smooth thoroughly, rubella pruritus, pediatric epilepsy scared, conjunctival congestion, cataracta, furuncle swelling toxin, diseases such as tetanus.Modern medicine proof Periostracum Cicadae has extensive inhibition usefulness to cental system, and has stronger immunosuppressant and anti-allergic effects.
The Radix Gentianae bitter in the mouth, cold in nature.Return liver, gallbladder meridian.The clinical heat clearing and damp drying that cures mainly; The eliminating pathogen in the liver arresting convulsion.Jaundice due to damp-heat; The urine leaching pain; Swelling of the vulva pudendal pruritus; Damp-heat vaginal discharge; The feeling of fullness in the head headache of liver and gall excess-fire; Conjunctival congestion and swelling pain; Deaf ear is swollen; The hypochondriac pain bitter taste; Diseases such as convulsion with spasms.Modern pharmacology confirms multiple pharmacologically actives such as Radix Gentianae has hepatic cholagogic, and diuresis is antibiotic.
The Radix Paeoniae Alba goes into liver, spleen channel, has nourishing blood to suppress the hyperactive liver, slow middle pain relieving, and yin fluid astringing is received the effect of antiperspirant.Cure mainly the breast abdomen pain over the hypochondriac region, dysentery stomachache, spontaneous sweating, fever due to yin deficiency, menoxenia, metrorrhagia, diseases such as leukorrhagia.Herba Menthae is one of Chinese conventional Chinese medicine.It is hot cold property sweating and heat resolving medicine, controls influenza, headache, conjunctival congestion, fever of the body, throat, dental bed disease such as swell and ache.But external training the mind dysmenorrhoea, skin pruritus, erythra and eczema etc.The Herba Menthae of light friend Greenhouse Fruit Picking is again the fresh vegetable on the dining table in the Spring Festival.Clearly good to eat.Usually with Herba Menthae for tea, clearing away heart-fire makes eye bright.Modern medicine proof Herba Menthae has very strong antiviral and antibacterial activity, and has certain antiallergic activity.
Radix Scutellariae and Flos Lonicerae can play the cooperative effect of dispelling phlegm and eliminating dampness, removing pathogenic heat from blood and toxic substance from the body in the Chinese medicine composition of the present invention.Windproof and Rhizoma Chuanxiong then can blood circulation promoting and blood stasis dispelling, the removing mass collateral dredging; Herba Artemisiae Scopariae, Periostracum Cicadae, Herba Menthae and Herba Taraxaci share can clearing away heat-damp and promoting diuresis, dispelling wind and heat pathogens, dispersing swelling and dissipating binds symptom.Rhizoma Chuanxiong and Radix Scutellariae can heat clearing and damp drying, eliminating stagnation is induced sweat.The Radix Paeoniae Alba and Radix Gentianae can nourishing blood to suppress the hyperactive liver, nourishing blood to tranquillize the mind.The Radix Glycyrrhizae coordinating the actions of various ingredients in a prescription.All medicines share, and play the effect of dispersing swelling and dissipating binds, activating blood circulation to dissipate blood stasis, dispelling phlegm and eliminating dampness altogether.
The method for preparing Chinese medicine composition of the present invention is following: get each medical material of above-mentioned components by weight percent, add the 5-15 water doubly of medical material gross weight, soaked 10-60 minute, decoct 1-4 time; Each 1-3 hour, filter, merging filtrate, filtrate decompression is concentrated into the extractum of relative density 1.05-1.25; This relative density is the testing result under 60 degrees centigrade, adds ethanol to containing the alcohol amount for 60-90% (v/v), leaves standstill 24 hours; Get supernatant, reclaim ethanol, promptly get to concentrating.
The above-mentioned Chinese medicine composition of the present invention can further be prepared into pharmaceutical preparation commonly used clinically, is preferably mixture, tablet, capsule.
The present invention also discloses a kind of purposes of above-mentioned Chinese medicine composition, the purposes of promptly above-mentioned Chinese medicine composition in preparation treatment conjunctivitis medicine.Wherein said conjunctivitis can be simple struvite conjunctivitis, viral conjunctivitis, bacterial conjunctivitis or anaphylaxis conjunctivitis.The embodiment of the invention 4 confirms that through the antiinflammatory action of investigating Chinese medicine composition xylol induced mice inflammatory model of the present invention Chinese medicine composition provided by the invention can have significant anti-inflammatory efficacy; Its antiphlogistic effects is superior to hydrocortisone, wherein the antiphlogistic effects of high dose group and middle dose groups compare with hydrocortisone and have significant difference (
P＜0.05), when this shows the struvite conjunctivitis of traditional Chinese medicine composition for treating of the present invention effect comprehensively, have obvious synergism, obtained unforeseeable curative effect of medication.The embodiment of the invention 5 finds that to the common pathogen fungistatic effect Chinese medicine composition of the present invention can play the inhibition effect to most pathogenic bacterium through investigating Chinese medicine composition of the present invention under very low crude drug concentration, and this shows that the present invention has has a broad antifungal spectrum, treatment advantage that antibiotic concentration is low when being used for the treatment of bacterial conjunctivitis.The embodiment of the invention 6 finds that through investigating the clinical therapeutic efficacy of Chinese medicine composition of the present invention to the viral conjunctivitis patient Chinese medicine composition medication of the present invention can obviously improve the symptom of popular hemorrhagic conjunctivitis after 5 days, and patient's cure rate is high.The embodiment of the invention 7 has been investigated the therapeutic effect of Chinese medicine composition of the present invention to anaphylaxis conjunctivitis; Find that Chinese medicine composition of the present invention can alleviate the anaphylaxis conjunctivitis symptom, its total effective rate for anaphylaxis conjunctivitis is significantly higher than the agent of common drug Cetirizine hydrochloride Tablets.
In a word, the present invention compared with prior art has the activity of well treated conjunctivitis, and the present invention is pure Chinese medicinal preparation, to human body particularly to the liver avirulence.When the present invention used as the conjunctivitis medicine, drug effect was comprehensive, in dispersing the stagnated live-QI to relieve the stagnation of QI, spleen invigorating food stagnation removing, can also obtain the effect of activating blood circulation to dissipate blood stasis, dispelling phlegm and eliminating dampness, and the conjunctivitis conditions of patients is taken a turn for the better; And Chinese medicine composition preparation of the present invention is simple, and nontoxic basically, raw material is easy to get, and is suitable for popular use, has the good clinical application prospect.
The specific embodiment
Below further describe the present invention through the specific embodiment, but the present invention is not limited only to following examples.Within the scope of the invention perhaps in not breaking away from content of the present invention, spirit and scope; Chinese medicine composition of the present invention is suitably improved, replaces the identical component of effect; Will become apparent to those skilled in the art that they all are regarded as is included within the scope of the present invention.
First, the preparation of Chinese medicine composition of the present invention
Embodiment 1 Chinese medicine composition mixture of the present invention
Prescription: 15 parts of Radix Scutellariaes, 6 parts of Flos Loniceraes, windproof 10 parts, 10 parts of Herba Artemisiae Scopariaes, 10 parts of Rhizoma Chuanxiongs, 20 parts of Herba Taraxacis, 20 parts of Periostracum Cicadaes, 10 parts of Radix Gentianaes, 5 parts of the Radix Paeoniae Albas, 5 parts of Herba Menthaes, 10 parts in Radix Glycyrrhizae.
Method for preparing: get each medical material of above-mentioned components by weight percent, add 5 times water of medical material gross weight, soaked 30 minutes, decoct each 2 hours 2 times; Filter, merging filtrate, filtrate decompression is concentrated into the extractum of relative density 1.1, and this relative density is the testing result under 60 degrees centigrade, and adding ethanol is 75% (v/v) to containing the alcohol amount; Left standstill 24 hours, and got supernatant, reclaim ethanol and concentrate, add water to 1000ml; Stir, packing, flowing steam sterilization 35min promptly gets mixture.
Embodiment 2 Chinese medicine composition tablets of the present invention
Prescription: 15 parts of Radix Scutellariaes, 6 parts of Flos Loniceraes, windproof 10 parts, 10 parts of Herba Artemisiae Scopariaes, 10 parts of Rhizoma Chuanxiongs, 20 parts of Herba Taraxacis, 20 parts of Periostracum Cicadaes, 10 parts of Radix Gentianaes, 5 parts of the Radix Paeoniae Albas, 5 parts of Herba Menthaes, 10 parts in Radix Glycyrrhizae.
Method for preparing: get each medical material of above-mentioned components by weight percent, add 10 times water of medical material gross weight, soaked 60 minutes, decoct 1 time; Each 1 hour, filter, merging filtrate, filtrate decompression is concentrated into the extractum of relative density 1.25; This relative density is the testing result under 60 degrees centigrade, and adding ethanol is 80% (v/v) to containing the alcohol amount, leaves standstill 24 hours, gets supernatant; Reclaim ethanol to concentrated, vacuum drying, granulation, tabletting promptly gets.
Embodiment 3 Chinese medicinal composition capsules of the present invention
Prescription: 15 parts of Radix Scutellariaes, 6 parts of Flos Loniceraes, windproof 10 parts, 10 parts of Herba Artemisiae Scopariaes, 10 parts of Rhizoma Chuanxiongs, 20 parts of Herba Taraxacis, 20 parts of Periostracum Cicadaes, 10 parts of Radix Gentianaes, 5 parts of the Radix Paeoniae Albas, 5 parts of Herba Menthaes, 10 parts in Radix Glycyrrhizae.
Method for preparing: get each medical material of above-mentioned components by weight percent, add 8 times water of medical material gross weight, soaked 45 minutes, decoct 4 times; Each 1.5 hours, filter, merging filtrate, filtrate decompression is concentrated into the extractum of relative density 1.2; This relative density is the testing result under 60 degrees centigrade, and adding ethanol is 90% (v/v) to containing the alcohol amount, leaves standstill 24 hours, gets supernatant; Reclaim ethanol to concentrating, vacuum drying is granulated, and encapsulatedly promptly gets.
Second portion, the pharmacodynamics of Chinese medicine composition of the present invention is investigated
The antiinflammatory action of embodiment 4 Chinese medicine composition xylol induced mice inflammatory models of the present invention
Hydrocortisone is that synthetic also is naturally occurring glucocorticoid, after hydrocortisone gets into cell, activates cytoplasmic receptor; Get into nucleus after the allosteric; Combine with the DNA response element, cause the inhibition of genetic transcription or induce, the expression of inflammation GAP-associated protein GAP is changed.Hydrocortisone has stronger anti-inflammatory activity, is usually used in the treatment of arthritis, conjunctivitis clinically.
Experimental technique:
50 KM mices, male and female half and half, body weight 25-30 gram; Be divided into 5 groups at random by body weight, i.e. dose groups in model control group, combination group high dose group, the compositions, compositions low dose group, positive controls; Every group 10, each administration group mice gives following medicine respectively:
Model control group: irritate stomach and give normal saline with volume;
Positive controls: irritate the hydrocortisone drug solution that stomach gives 5mg/kg;
The compositions high dose group: irritate stomach and give 50mg/kg embodiment 1 Chinese medicine composition, Chinese medicine composition is by the crude drug amount;
Dose groups in the compositions: irritate stomach and give 20 mg/kg embodiment 1 Chinese medicine composition, Chinese medicine composition is by the crude drug amount;
The compositions low dose group: irritate stomach and give 5 mg/kg embodiment 1 Chinese medicine composition, Chinese medicine composition is by the crude drug amount;
Each administration group is administered once every day, successive administration 7d.Get xylene 20 μ l after the last administration, be applied to each mouse right ear.Get after 30 minutes and respectively receive reagent 0.03 ml evenly to be applied to mouse right ear respectively, auris dextra puts to death for xylene after 3.5 hours, and mensuration is respectively organized the mice left and right sides ear method of double differences.Ear method of double differences assay method: the place cuts two ears along the auricle baseline, the same position of ear lays auricle with the 8mm card punch in the left and right sides, weighs, and the ear method of double differences=auris dextra sheet weight-left auricle is heavy.The ear method of double differences can be used as estimates the antiinflammatory index.
Experimental result:Measure each experimental mice ear method of double differences and estimate the antiphlogistic effects of each medication group medicine.Measure the result and see table 2.
Each experimental mice ear method of double differences of table 1 relatively
| Group | n | The ear method of double differences (mg) |
| Model control group | 10 | 8.20±1.18 |
| Positive controls | 10 | 6.24±1.51 * |
| The compositions high dose group | 10 | 2.81±1.84 **## |
| Dose groups in the compositions | 10 | 4.45±1.54 **# |
| The compositions low dose group | 10 | 5.93±1.24 * |
Compare with model control group,
* P＜0.05; Compare with model control group,
* P＜0.01;
Compare with positive controls,
# P＜0.05; Compare with positive controls,
## P＜0.01.
Result's demonstration gives positive drug and Chinese medicine composition of the present invention all can be obtained significant antiphlogistic effects; The antiphlogistic effects of Chinese medicine composition high dose group wherein of the present invention and positive controls have utmost point significant difference; Chinese medicine composition low dose group and positive controls have significant difference, and this shows that the high dose group of Chinese medicine composition of the present invention and the antiphlogistic effects of low dose group will significantly be superior to positive controls.
The external bacteriostatic experiment of embodiment 5 Chinese medicine compositions of the present invention
This tests employed strain and culture medium is respectively Jia Xingrongxuexinglianqiujun (32209), beta hemolytic streptococcus (32210), ETEC (44102), proteus vulgaris (49101), Salmonella paratyphi A (50001), shigella dysenteriae (51252), staphylococcus aureus [26111 (5)], hemophilus influenza (58529-4), nutrient agar (in be stranded pharmaceutical biological product calibrating institute); Opacity tube (Chinese bacterial turbidity standard, the biological combinations calibrating of Chinese medicine institute).
External bacteriostatic experiment: 1. prepare the pastille agar plate.With being tried the culture medium of thing by doubling dilution preparation different pharmaceutical concentration, required separately pH value is modulated in heating, and 121 ℃ of sterilization 30 min are chilled to 45 ℃.Pour into into aseptic flat board (plate d=
65 mm, 10 ml/ plates), finally make and contain the extension rate that is tried thing stock solution (2g/ml) in the culture medium and be respectively l:2,1:4 ... 1:1024.Do blank culture medium separately simultaneously.2. inoculation.Get the bacterium in young age that reaches the third generation, divide
Not using 0.9% sodium chloride solution is the bacterium liquid to be checked of 108 cfu/ml by standard opacity tube corrected concentrations, is inoculated in the agar surface of pastille separately of different doubling dilutions respectively, inoculates parallel point 3 points simultaneously, makes contain 2 one bacterium liquid at every.The liquid-drop diameter of each inoculation point is 5-8 mm.After treating inoculation point drying, upset is dull and stereotyped cultivates 20 h observed results (doing blank simultaneously) in 36 ℃ of constant incubators.3. criterion.Being tried substrate concentration with the minimum dilution on the agar plate that bacterium colony do not occur is its minimum inhibitory concentration (MIC).
Chinese medicine composition is as shown in table 2 to the minimal inhibitory concentration of each pathogenic strain in this experiment:
Table 2 Chinese medicine composition of the present invention is to the minimal inhibitory concentration of each pathogenic strain
| Bacterial strain | Minimal inhibitory concentration (MIC, g/ml) | The drug dilution degree |
| Jia Xingrongxuexinglianqiujun | 0.008 | 1：256 |
| Beta hemolytic streptococcus | 0.016 | 1：128 |
| Escherichia coli | 0.032 | 1：64 |
| Proteus vulgaris | 0.016 | 1：128 |
| Salmonella paratyphi A | 0.032 | 1：64 |
| Shigella dysenteriae | 0.064 | 1：32 |
| Hemophilus influenza | 0.016 | 1：128 |
| Staphylococcus aureus | 0.032 | 1：64 |
The result shows that Chinese medicine composition of the present invention all has good fungistatic effect to most pathogenic bacterium, and this has crucial treatment meaning for receiving the extraneous eyes conjunctiva that infects the most easily.
Embodiment 6 Chinese medicine compositions of the present invention are to the clinical therapeutic efficacy of viral conjunctivitis
The infectiousness oculopathy that belongs to outbreak of epidemic that epidemic hemorrhagic conjunctivitis system is caused by a kind of novel pico+ribonucleic acid+virus, this disease morbidity is anxious, and infectiousness is strong, the western medicine poor effect of using clinically at present.
1 clinical data
This group is observed case 50 examples, male's 38 examples wherein, and women's 12 examples, are the eyes morbidity at 32 years old mean age.The diagnostic criteria of hemorrhagic conjunctivitis is: patient's eyes successively or occur puckery pain simultaneously, the photophobia difficulty is opened, the gluing closure of lower eyelid on the morning time-out.Eyelid swelled during examination of eyes, conjunctival congestion, the some lamellar is hemorrhage, and pseudomembrane appears in patient's conjunctiva, angle damage on the cornea, fluorescence staining is point-like or slice colouring.
2 Therapeutic Method
For oral administration from intending the conjunctivitis mixture.Prescription: Radix Scutellariae 15 grams, Flos Lonicerae 6 grams, windproof 10 grams, Herba Artemisiae Scopariae 10 grams, Rhizoma Chuanxiong 10 grams, Herba Taraxaci 20 grams, Periostracum Cicadae 20 grams, Radix Gentianae 10 grams, the Radix Paeoniae Alba 5 grams, Herba Menthae 5 grams, Radix Glycyrrhizae 10 grams.Be decocted in water for oral dose 1 dose of every day, 2 times/d, successive administration 5 days.
3 therapeutic effect
Judge the therapeutic effect of medicine in the therapeutic process to hemorrhagic conjunctivitis.Employed curative effect judging standard is:
A) recovery from illness: ophthalmalgia disappears, no sensation of dryness, and no gum adacrya, no photophobia is shed tears.Inspection: eyelid does not have swelling, and conjunctiva does not have hyperemia, no pseudomembrane and hemorrhage, corneal transparency.
B) take a turn for the better: ophthalmalgia disappears, and no photophobia is shed tears, and sensation of dryness is arranged.Inspection: eyelid does not have swelling, conjunctival congestion but do not have pseudomembrane, corneal transparency.
Chinese medicine composition of the present invention is presented at 50 routine hemorrhagic conjunctivitis patient's medications after 5 days to the therapeutic effect of hemorrhagic conjunctivitis, and patient's the state of an illness recovery from illness all occurs or takes a turn for the better, and 41 examples of wherein fully recovering account for 82 %; 9 examples that take a turn for the better account for 18 %.This shows that Chinese medicine composition of the present invention has significant therapeutical effect aspect the treatment hemorrhagic conjunctivitis.
Embodiment 7 Chinese medicine compositions of the present invention are to the therapeutical effect of anaphylaxis conjunctivitis
Anaphylaxis conjunctivitis is a para-immunity property disease, and significantly ophthalmic pruritus, conjunctival congestion, papillary hypertrophy and follicle hypertrophy are arranged usually, the obviously influence of the many nothings of corneal, and the long more sings and symptoms of the course of disease is heavy more.The treatment anaphylaxis conjunctivitis is main with eye local application, and main purpose is mitigation symptoms and avoids taking place sequela.Antihistaminic, vasoconstrictor, mast cell stabilizers, NSAID, glucocorticoid etc. are the common drug of topical therapeutic anaphylaxis conjunctivitis in recent years.
1 clinical data
1) includes standard in
Seasonal allergic conjunctivitis is except that seasonality outbreak and symptom, sign integration are all relatively low, and other clinical characters and perennial allergic conjunctivitis are quite similar, so include in both are unified.Diagnosis is main with reference to " Chinese ophthalmology " (1) symptom: ophthalmic pruritus, shed tears, burning sensation, foreign body sensation, photophobia and secretions increases (being mostly mucus).(2) sign: conjunctival congestion, edema, palpebral conjunctiva nipple follicle hypertrophy.
2) exclusion standard
With eye patients such as keratitis, xerophthalmia, glaucomas; The person that executed the ophthalmologic operation in nearly 1 month; Use possibly influence the patient of other hydryllin, mast cell stabilizers and corticosteroid collyrium, nasal mist or the systemic drug of result of study; Intentionally, the patient of serious primary disease such as brain, liver, kidney and hemopoietic system; Not by the regulation medication, can't judge the infull person of curative effect or data.
3) physical data
Meet above-mentioned standard through the seasonal allergic conjunctivitis made a definite diagnosis 66 examples and perennial allergic conjunctivitis 24 examples totally 90 examples.Making a definite diagnosis the back adopts district's group method at random that prescription on individual diagnosis person is divided into two groups: 45 examples are organized in treatment, male 19 examples, women 26 examples; Age 19-66 year (average 36.2 years old).Matched group 45 examples, male 21 examples, women 24 examples; Age 17-65 year (average 35.8 years old).Two groups of physical data are through statistical procedures, and the difference not statistically significant (P>0.05), have comparability.
2 Therapeutic Method
For oral administration from intending the conjunctivitis mixture.Prescription: Radix Scutellariae 15 grams, Flos Lonicerae 6 grams, windproof 10 grams, Herba Artemisiae Scopariae 10 grams, Rhizoma Chuanxiong 10 grams, Herba Taraxaci 20 grams, Periostracum Cicadae 20 grams, Radix Gentianae 10 grams, the Radix Paeoniae Alba 5 grams, Herba Menthae 5 grams, Radix Glycyrrhizae 10 grams.Be decocted in water for oral dose 1 dose of every day, 2 times/d, successive administration 5 days.Matched group is taken Cetirizine hydrochloride Tablets agent (the special medicine company limited of southern Shandong shellfish is produced 10mg/ sheet, a slice on the one).After treatment back 3 days, 5 days, 7 days and drug withdrawal, 1 week checked and followed up a case by regular visits to respectively, record eye subjective symptom and slit lamp examination palpebra inferior, conjunctiva, cornea.
3, therapeutic effect
Curative effect determinate standard: adopt " clinical characters of anaphylaxis conjunctivitis ".Symptom and sign standards of grading evaluation index: ophthalmic pruritus, shed tears foreign body sensation, eyelid nipple, palpebral follicles, secretions, conjunctival congestion, chemosis.And calculating symptom integral.Computing formula: total mark * 100% before total mark decline index=(total mark before the treatment-treatment back total mark)/treatment.Produce effects: integration reduces>70%; Effectively: integration reduces 30%-70%; Invalid: integration reduces < 30%.
Table 2 Chinese medicine composition of the present invention is to the therapeutic effect of anaphylaxis conjunctivitis
| Group | N | Produce effects | Effectively | Invalid | Total effective rate |
| The administration group | 45 | 24 * | 18 * | 3 | 93.3% * |
| Matched group | 45 | 15 | 9 | 11 | 75.6% |
Compare with matched group,
*P＜0.05
Can find out that by table 2 Chinese medicine composition of the present invention significantly is superior to cetirizine hydrochloride for the therapeutic effect of anaphylaxis conjunctivitis.
Claims (4)
1. Chinese medicine composition of treating conjunctivitis; It is characterized in that making: 15 parts of Radix Scutellariaes, 6 parts of Flos Loniceraes, windproof 10 parts, 10 parts of Herba Artemisiae Scopariaes, 10 parts of Rhizoma Chuanxiongs, 20 parts of Herba Taraxacis, 20 parts of Periostracum Cicadaes, 10 parts of Radix Gentianaes, 5 parts of the Radix Paeoniae Albas, 5 parts of Herba Menthaes, 10 parts in Radix Glycyrrhizae by the raw material of following weight portion.
2. the Chinese medicine composition of treatment conjunctivitis as claimed in claim 1 is characterized in that said pharmaceutical composition is mixture, tablet or capsule.
3. according to claim 1 or claim 2 the method for preparing of Chinese medicine composition of treatment conjunctivitis is characterized in that may further comprise the steps: get each medical material, add the 5-15 water doubly of medical material gross weight; Soaked 10-60 minute, and decocted 1-4 time, each 1-3 hour; Filter, merging filtrate, filtrate decompression is concentrated into the extractum of relative density 1.05-1.25; This relative density is the testing result under 60 degrees centigrade, adds ethanol to containing the alcohol amount for 60-90%v/v, leaves standstill 24 hours; Get supernatant, reclaim ethanol, promptly get to concentrating.
4. according to claim 1 or claim 2 the purposes of Chinese medicine composition in preparation treatment conjunctivitis medicine of treatment conjunctivitis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210380257.5A CN102836228B (en) | 2012-10-10 | 2012-10-10 | Chinese medicinal composition for treating conjunctivitis and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210380257.5A CN102836228B (en) | 2012-10-10 | 2012-10-10 | Chinese medicinal composition for treating conjunctivitis and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102836228A true CN102836228A (en) | 2012-12-26 |
| CN102836228B CN102836228B (en) | 2014-06-25 |
Family
ID=47364131
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210380257.5A Active CN102836228B (en) | 2012-10-10 | 2012-10-10 | Chinese medicinal composition for treating conjunctivitis and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102836228B (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103110743A (en) * | 2013-03-08 | 2013-05-22 | 崔合芳 | Traditional Chinese medicine composition for treating or preventing neurasthenia and preparation method thereof |
| CN103251744A (en) * | 2013-04-06 | 2013-08-21 | 李彩萍 | Traditional Chinese medicine composition for treating keratitis and conjunctivitis |
| CN103505680A (en) * | 2013-08-31 | 2014-01-15 | 宋景戈 | Traditional Chinese medicine composition for treating acute conjunctivitis |
| CN104288626A (en) * | 2014-10-28 | 2015-01-21 | 青岛华仁技术孵化器有限公司 | Medicine for treating acute conjunctivitis |
| CN104383275A (en) * | 2014-10-16 | 2015-03-04 | 宁波大学 | Chinese herbal preparation used for curing allergic conjunctivitis |
| CN104887973A (en) * | 2015-07-04 | 2015-09-09 | 青岛辰达生物科技有限公司 | Traditional Chinese medicine composition for treating acute catarrhal conjunctivitis with cough |
| CN105267434A (en) * | 2015-10-27 | 2016-01-27 | 叶宗耀 | Traditional Chinese medicine composition for treating allergic conjunctivitis and preparation method of traditional Chinese medicine composition for treating allergic conjunctivitis |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1850191A (en) * | 2006-03-14 | 2006-10-25 | 北京国丹药物技术开发有限公司 | Eye drops with capillary artemisia, cape jasmine and baikal skullcap root, and its preparing method |
| CN101168029A (en) * | 2007-11-06 | 2008-04-30 | 郭太平 | Method for manufacturing liver-smoothing, qi-regulating and detoxification capsule |
| CN101181365A (en) * | 2007-11-15 | 2008-05-21 | 王玉鑫 | Chinese medicine composition orally taken for curing tonsillitis |
| CN101879223A (en) * | 2009-05-05 | 2010-11-10 | 天津市圣世莱科技有限公司 | Chinese medicinal composition for treating livestock and poultry viral diseases and preparation method thereof |
| CN102366488A (en) * | 2011-09-28 | 2012-03-07 | 邓华伦 | Chinese herbal medicine for treating infectious conjunctivitis |
| CN102423349A (en) * | 2011-11-01 | 2012-04-25 | 文登市口腔医院米山路口腔诊所 | Traditional Chinese medicine for curing acute pinkeye |
| CN102688301A (en) * | 2012-05-31 | 2012-09-26 | 王亚明 | Traditional Chinese medicine lotion for treating acute conjunctivitis and preparation method thereof |
-
2012
- 2012-10-10 CN CN201210380257.5A patent/CN102836228B/en active Active
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1850191A (en) * | 2006-03-14 | 2006-10-25 | 北京国丹药物技术开发有限公司 | Eye drops with capillary artemisia, cape jasmine and baikal skullcap root, and its preparing method |
| CN101168029A (en) * | 2007-11-06 | 2008-04-30 | 郭太平 | Method for manufacturing liver-smoothing, qi-regulating and detoxification capsule |
| CN101181365A (en) * | 2007-11-15 | 2008-05-21 | 王玉鑫 | Chinese medicine composition orally taken for curing tonsillitis |
| CN101879223A (en) * | 2009-05-05 | 2010-11-10 | 天津市圣世莱科技有限公司 | Chinese medicinal composition for treating livestock and poultry viral diseases and preparation method thereof |
| CN102366488A (en) * | 2011-09-28 | 2012-03-07 | 邓华伦 | Chinese herbal medicine for treating infectious conjunctivitis |
| CN102423349A (en) * | 2011-11-01 | 2012-04-25 | 文登市口腔医院米山路口腔诊所 | Traditional Chinese medicine for curing acute pinkeye |
| CN102688301A (en) * | 2012-05-31 | 2012-09-26 | 王亚明 | Traditional Chinese medicine lotion for treating acute conjunctivitis and preparation method thereof |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103110743A (en) * | 2013-03-08 | 2013-05-22 | 崔合芳 | Traditional Chinese medicine composition for treating or preventing neurasthenia and preparation method thereof |
| CN103251744A (en) * | 2013-04-06 | 2013-08-21 | 李彩萍 | Traditional Chinese medicine composition for treating keratitis and conjunctivitis |
| CN103505680A (en) * | 2013-08-31 | 2014-01-15 | 宋景戈 | Traditional Chinese medicine composition for treating acute conjunctivitis |
| CN103505680B (en) * | 2013-08-31 | 2015-04-08 | 宋景戈 | Traditional Chinese medicine composition for treating acute conjunctivitis |
| CN104383275A (en) * | 2014-10-16 | 2015-03-04 | 宁波大学 | Chinese herbal preparation used for curing allergic conjunctivitis |
| CN104288626A (en) * | 2014-10-28 | 2015-01-21 | 青岛华仁技术孵化器有限公司 | Medicine for treating acute conjunctivitis |
| CN104887973A (en) * | 2015-07-04 | 2015-09-09 | 青岛辰达生物科技有限公司 | Traditional Chinese medicine composition for treating acute catarrhal conjunctivitis with cough |
| CN105267434A (en) * | 2015-10-27 | 2016-01-27 | 叶宗耀 | Traditional Chinese medicine composition for treating allergic conjunctivitis and preparation method of traditional Chinese medicine composition for treating allergic conjunctivitis |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102836228B (en) | 2014-06-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102836228B (en) | Chinese medicinal composition for treating conjunctivitis and preparation method and application thereof | |
| CN102198236B (en) | Chinese medicine composition for treating acute sinusitis and preparation method thereof | |
| CN103585433B (en) | Traditional Chinese medicine composition for treating oral ulcer | |
| CN102139030B (en) | Oral Chinese herbal preparation for treating gingivitis and preparation method thereof | |
| CN102205026A (en) | Chinese medicinal composition for treating children chronic sinusitis and preparation method thereof | |
| CN105560372A (en) | Traditional Chinese medicine spray for treating rhinitis and preparation method thereof | |
| CN103182023A (en) | Medicine for treating chronic pharyngitis and preparation method thereof | |
| CN105213941A (en) | A kind of Chinese medicine composition being used for the treatment of infantile diarrhea and preparation method thereof | |
| CN103263531B (en) | Chinese medicine composition for treating prosopalgia and preparation method thereof | |
| CN104013846A (en) | Traditional Chinese medicine composition for treating dental ulcer and application thereof | |
| CN102614413B (en) | Chinese medicinal composition for treating sinusitis in children and preparation method thereof | |
| CN104096141A (en) | Traditional Chinese medical composition for treating allergic conjunctivitis | |
| CN104983968B (en) | Antipyretic traditional Chinese medicine composition and preparation method thereof | |
| CN105535495A (en) | Chinese medicinal composition for treating esophageal cancer by reinforcing vital essence and strengthening primordial qi and preparation method | |
| CN104984292A (en) | Medicine composition for treating mycoplasmal pneumonia and preparation method thereof | |
| CN102940753B (en) | Pills for treating glaucoma and preparation method | |
| CN107753664B (en) | Traditional Chinese medicine composition for treating allergic rhinitis and preparation method thereof | |
| CN104352794A (en) | Traditional Chinese medicine preparation for treating lung yin deficiency type xerophthalmia | |
| CN104173830A (en) | Medicament for reconciling interior syndromes and relieving exterior syndromes for high fever of cold in winter and preparation method thereof | |
| CN103110737B (en) | Traditional Chinese medicine composition for treating gynecologic inflammation and preparation method thereof | |
| CN104274750A (en) | Traditional Chinese medicinal composition for treating acute bronchitis and upper respiratory infection | |
| CN103263614A (en) | Pharmaceutical composition for preventing or treating vaginitis | |
| CN100486613C (en) | Coryza-treating pharmaceutical compositions and its preparing process and uses | |
| CN104689073A (en) | Medicine for treating yin deficiency and heat-poison type lung cancer and preparation method thereof | |
| CN104491013A (en) | Application of traditional Chinese medicine composition to preparation of drug for treating allergic conjunctivitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: CUI HEFANG Free format text: FORMER OWNER: CHEN XINGWANG Effective date: 20130508 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 276017 LINYI, SHANDONG PROVINCE TO: 266200 QINGDAO, SHANDONG PROVINCE |
|
| TA01 | Transfer of patent application right |
Effective date of registration: 20130508 Address after: 266200 Jimo, Shandong, the Yellow River Road No. two, No. 182, No. Applicant after: Cui Hefang Address before: Three village Chu Dun Zhen 276017 Shandong province Linyi city Luozhuang District No. 89 group Applicant before: Chen Xingwang |
|
| ASS | Succession or assignment of patent right |
Owner name: BINZHOU MEDICAL UNIVERSITY HOSPITAL Free format text: FORMER OWNER: CUI HEFANG Effective date: 20140505 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| C53 | Correction of patent of invention or patent application | ||
| CB03 | Change of inventor or designer information |
Inventor after: Li Weiguo Inventor after: Gong Yuerong Inventor before: Li Weiguo Inventor before: Gong Yuerong |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 266200 QINGDAO, SHANDONG PROVINCE TO: 256600 BINZHOU, SHANDONG PROVINCE |
|
| TA01 | Transfer of patent application right |
Effective date of registration: 20140505 Address after: 256600 No. two, No. 661, the Yellow River Road, Shandong, Binzhou Applicant after: Binzhou Medical University Hospital Address before: 266200 Jimo, Shandong, the Yellow River Road No. two, No. 182, No. Applicant before: Cui Hefang |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: CUI HEFANG Free format text: FORMER OWNER: BINZHOU MEDICAL UNIVERSITY HOSPITAL Effective date: 20140728 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 256600 BINZHOU, SHANDONG PROVINCE TO: 266200 QINGDAO, SHANDONG PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20140728 Address after: 266200 Jimo, Shandong, the Yellow River Road No. two, No. 182, No. Patentee after: Cui Hefang Address before: 256600 No. two, No. 661, the Yellow River Road, Shandong, Binzhou Patentee before: Binzhou Medical University Hospital |
|
| ASS | Succession or assignment of patent right |
Owner name: NANTONG HONGCI PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: CUI HEFANG Effective date: 20140829 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 266200 QINGDAO, SHANDONG PROVINCE TO: 226200 NANTONG, JIANGSU PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20140829 Address after: 226200 Qidong chemical industry park, Jiangsu, Nantong Patentee after: NANTONG HONGCI PHARMACEUTICAL CO., LTD. Address before: 266200 Jimo, Shandong, the Yellow River Road No. two, No. 182, No. Patentee before: Cui Hefang |